Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04904276 · ClinicalTrials.gov registry record
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
A clinical trial, sponsored by Rigel Pharmaceuticals.
- Terminated
- Registry status
- 16
- Enrollment target
NCT04904276: Clinical Trial study, sponsored by Rigel Pharmaceuticals.
NCT04904276 is a clinical trial that was terminated before completion, run by Rigel Pharmaceuticals. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04904276 was terminated before completion, sponsored by Rigel Pharmaceuticals.
- TERMINATED
- Registry status
- 16 participants
- Enrollment target
Study Summary
Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP in adult patients who have an insufficient response to prior therapy (steroids ± immunoglobulins).
Primary Outcome
Changes in fostamatinib dosing
Interventions
- DRUG Fostamatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2022-11-17 |
Why NCT04904276 stopped before completion
NCT04904276 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Fostamatinib is the first listed.
NCT04904276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04904276 about?
NCT04904276 is a clinical study titled "Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy". Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP in adult patients who have an insufficient response to prior therapy (steroids ± immunoglobulins).
What is the current status of trial NCT04904276?
This trial is currently terminated. The enrollment target is 16 participants. The study started on 2021-05-18. Estimated completion is 2022-11-17.
What interventions are being tested in trial NCT04904276?
The interventions under investigation include: Fostamatinib (DRUG).
Who is sponsoring clinical trial NCT04904276?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI